These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 1348778

  • 1. A novel methodology for the establishment of neuroblastoma cell lines from metastatic marrow. Expression of surface markers, neurofilaments, MDR-1 and myc proteins.
    Gazitt Y, He YJ, Graham-Pole J.
    J Immunol Methods; 1992 Apr 08; 148(1-2):171-8. PubMed ID: 1348778
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K.
    Cancer Res; 2001 Feb 15; 61(4):1637-44. PubMed ID: 11245477
    [Abstract] [Full Text] [Related]

  • 4. Development of a two color immunofluorescence stain and immunolocalization method for N-myc and c-myc oncoproteins with a newly generated mouse IgM anti N-myc antibody.
    Gazitt Y, He YJ, Erdos GW, Chang L, Ashktorab H, Cohen RJ.
    J Immunol Methods; 1992 Apr 08; 148(1-2):159-69. PubMed ID: 1564326
    [Abstract] [Full Text] [Related]

  • 5. Pleiotropic over-expression of multidrug-resistance-related genes is correlated to MYCN and max mRNA accumulation during tumour progression in the IGR-N-91 human neuroblastoma model.
    Cappellen D, Bénard J.
    Int J Cancer; 1997 Feb 07; 70(4):430-6. PubMed ID: 9033651
    [Abstract] [Full Text] [Related]

  • 6. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma.
    Dhooge CR, De Moerloose BM, Benoit YC, Van Roy N, Philippé, Laureys GG.
    Cancer; 1997 Oct 01; 80(7):1250-7. PubMed ID: 9317175
    [Abstract] [Full Text] [Related]

  • 7. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
    Kim DK, Alvarado CS, Abramowsky CR, Gu L, Zhou M, Soe MM, Sullivan K, George B, Schemankewitz E, Findley HW.
    Pediatr Dev Pathol; 2005 Oct 01; 8(6):621-9. PubMed ID: 16328668
    [Abstract] [Full Text] [Related]

  • 8. Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometry.
    Brotherick I, Shenton BK, Egan M, Cunliffe WE, Browell DA, Lunt LG, Young JR, Higgs MJ.
    Eur J Cancer; 1996 Dec 01; 32A(13):2334-41. PubMed ID: 9038618
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
    Cohn SL, Salwen H, Quasney MW, Ikegaki N, Cowan JM, Herst CV, Kennett RH, Rosen ST, DiGiuseppe JA, Brodeur GM.
    Oncogene; 1990 Dec 01; 5(12):1821-7. PubMed ID: 2284101
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An immunohistochemical analysis of mdr-1 and bcl-2 expressions in neuroblastoma.
    Kim CJ, Lee YA, Ahn HS, Yun CK, Kim CW, Chi JG.
    Pathol Res Pract; 1995 Oct 01; 191(10):1010-5. PubMed ID: 8838369
    [Abstract] [Full Text] [Related]

  • 15. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.
    Meck MM, Wierdl M, Wagner LM, Burger RA, Guichard SM, Krull EJ, Harris LC, Potter PM, Danks MK.
    Cancer Res; 2001 Jul 01; 61(13):5083-9. PubMed ID: 11431345
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T, Gotoh T, Yagyu S, Kuroda H, Iehara T, Hosoi H, Ohta S, Ohira M, Nakagawara A.
    Cancer Lett; 2013 Apr 30; 331(1):115-21. PubMed ID: 23268333
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients.
    Wagner LM, Guichard SM, Burger RA, Morton CL, Straign CM, Ashmun RA, Harris LC, Houghton PJ, Potter PM, Danks MK.
    Cancer Res; 2002 Sep 01; 62(17):5001-7. PubMed ID: 12208753
    [Abstract] [Full Text] [Related]

  • 19. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
    Volm M, Kästel M, Mattern J, Efferth T.
    Cancer; 1993 Jun 15; 71(12):3981-7. PubMed ID: 8099529
    [Abstract] [Full Text] [Related]

  • 20. Multidrug resistance in human neuroblastoma cells.
    LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL.
    J Pediatr Surg; 1991 Sep 15; 26(9):1107-12. PubMed ID: 1719182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.